Transmembrane protein differentially expressed in cancer
US7105315B2 · kind B2 · utility
9Cited by
0References
9Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jul 1, 2002 |
| Grant date | Sep 12, 2006 |
| Priority date | — |
| Expiry date | May 17, 2024 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA01K2217/05
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The invention provides a transmembrane protein that is differentially expressed in neoplastic disorders. It also provides for the use of the protein, a cDNA encoding the protein, and antibodies that specifically bind the protein in various methods to diagnose, stage, treat, or monitor the treatment of a neoplastic disorder.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.